Munro Partners Makes New Investment in Eli Lilly and Company $LLY

Munro Partners bought a new position in shares of Eli Lilly and Company (NYSE:LLY) during the fourth quarter, Holdings Channel.com reports. The firm bought 38,520 shares of the company’s stock, valued at approximately $41,397,000. Eli Lilly and Company comprises 1.1% of Munro Partners’ investment portfolio, making the stock its 29th largest position.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Rakuten Investment Management Inc. lifted its position in Eli Lilly and Company by 248.2% during the 4th quarter. Rakuten Investment Management Inc. now owns 104,905 shares of the company’s stock valued at $113,164,000 after acquiring an additional 74,779 shares during the period. Codex Capital Asset Management L.L.C. lifted its position in Eli Lilly and Company by 8.1% during the 4th quarter. Codex Capital Asset Management L.L.C. now owns 18,380 shares of the company’s stock valued at $19,753,000 after acquiring an additional 1,380 shares during the period. Beacon Financial Advisory LLC lifted its position in Eli Lilly and Company by 34.8% during the 4th quarter. Beacon Financial Advisory LLC now owns 639 shares of the company’s stock valued at $687,000 after acquiring an additional 165 shares during the period. Abound Financial LLC purchased a new position in Eli Lilly and Company during the 4th quarter valued at about $161,000. Finally, Bluedoor Private Wealth LLC purchased a new position in Eli Lilly and Company during the 4th quarter valued at about $1,507,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly acquired 4E Therapeutics, a developer of non-opioid pain treatments, expanding its push into the painkiller market and broadening the company beyond obesity and diabetes drugs. Article Title
• Positive Sentiment: The company announced several pipeline updates, including progress on oral and early-stage candidates and a Phase 1 Alzheimer’s program, reinforcing investor focus on Lilly’s deep R&D pipeline. Article Title
• Positive Sentiment: Market research highlighting strong growth in the global GLP-1 receptor agonist market supports the long-term demand outlook for Lilly’s obesity and diabetes franchise, which remains a key driver of the stock. Article Title
• Neutral Sentiment: Healthcare stocks were generally firmer in afternoon trading, providing a modest sector tailwind rather than a company-specific catalyst. Article Title
• Neutral Sentiment: Several articles compared Lilly with Novo Nordisk amid ongoing obesity-drug competition, but these were mostly industry commentary and not new fundamental news for LLY. Article Title
• Negative Sentiment: Investors are also weighing a “quiet new threat” to Lilly’s GLP-1 business, as employer coverage and access concerns could slow adoption or limit growth for its top-selling obesity drugs. Article Title

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Truist Financial reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Barclays lifted their price target on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. Daiwa Securities Group increased their target price on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Leerink Partners set a $1,119.00 target price on Eli Lilly and Company in a research note on Tuesday, May 26th. Finally, Berenberg Bank increased their target price on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research note on Thursday, February 19th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,227.74.

Eli Lilly and Company Stock Performance

LLY stock opened at $1,122.47 on Wednesday. The stock has a market capitalization of $1.06 trillion, a PE ratio of 39.87, a price-to-earnings-growth ratio of 1.23 and a beta of 0.53. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,182.73. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock’s 50 day simple moving average is $1,006.08 and its 200 day simple moving average is $1,016.63.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date was Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.